Personalis Inc (PSNL) is a Healthcare · Diagnostics & Research company listed on NASDAQ. Price $16.33 (+0.62%), Market cap $0.74B, 52-week low–high $4.41 ~ $11.25.
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to
Financial statements, price targets, institutional (13F) holdings and related news for Personalis Inc are updated in real time on BlackAll Trade.
Personalis Inc trades at $16.33 (+0.62%). Real-time quotes and charts are available on BlackAll Trade.
Personalis Inc has a market cap of about $0.74B.
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test